CymaBay Therapeutics (NASDAQ:CBAY) Now Covered by StockNews.com

StockNews.com assumed coverage on shares of CymaBay Therapeutics (NASDAQ:CBAY) in a research report released on Saturday morning. The firm issued a sell rating on the biopharmaceutical company’s stock.

Other equities analysts also recently issued research reports about the stock. Raymond James downgraded shares of CymaBay Therapeutics from an outperform rating to a market perform rating and set a $32.50 price target on the stock. in a research note on Tuesday, February 13th. B. Riley reaffirmed a neutral rating and issued a $32.50 target price (up from $29.00) on shares of CymaBay Therapeutics in a research report on Tuesday, February 13th. Jonestrading reissued a hold rating on shares of CymaBay Therapeutics in a research report on Tuesday, February 13th. HC Wainwright restated a neutral rating and issued a $32.50 price objective on shares of CymaBay Therapeutics in a report on Thursday, February 29th. Finally, BTIG Research reiterated a neutral rating on shares of CymaBay Therapeutics in a report on Tuesday, February 13th. One investment analyst has rated the stock with a sell rating, eleven have assigned a hold rating and one has given a buy rating to the company’s stock. According to MarketBeat, the company has a consensus rating of Hold and a consensus target price of $28.65.

CymaBay Therapeutics Stock Performance

CymaBay Therapeutics stock opened at $32.48 on Friday. The stock has a fifty day moving average price of $32.42 and a 200 day moving average price of $25.23. CymaBay Therapeutics has a 52 week low of $7.26 and a 52 week high of $32.50. The firm has a market capitalization of $3.73 billion, a P/E ratio of -33.48 and a beta of 0.32.

CymaBay Therapeutics (NASDAQ:CBAY) last posted its quarterly earnings data on Wednesday, February 28th. The biopharmaceutical company reported ($0.35) EPS for the quarter, missing analysts’ consensus estimates of ($0.31) by ($0.04). The firm had revenue of $0.06 million for the quarter, compared to the consensus estimate of $0.42 million. As a group, equities analysts predict that CymaBay Therapeutics will post -1.38 EPS for the current year.

Insider Activity at CymaBay Therapeutics

In other news, Director Janet Dorling sold 6,000 shares of the business’s stock in a transaction on Monday, February 12th. The shares were sold at an average price of $31.97, for a total transaction of $191,820.00. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. Company insiders own 7.00% of the company’s stock.

Institutional Trading of CymaBay Therapeutics

Several large investors have recently modified their holdings of the business. Mirae Asset Global Investments Co. Ltd. boosted its holdings in CymaBay Therapeutics by 1.1% in the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 48,669 shares of the biopharmaceutical company’s stock valued at $1,150,000 after purchasing an additional 525 shares during the last quarter. Alps Advisors Inc. boosted its stake in shares of CymaBay Therapeutics by 1.1% during the 3rd quarter. Alps Advisors Inc. now owns 72,461 shares of the biopharmaceutical company’s stock valued at $1,080,000 after buying an additional 783 shares during the last quarter. Strategic Blueprint LLC grew its position in shares of CymaBay Therapeutics by 6.3% during the third quarter. Strategic Blueprint LLC now owns 16,800 shares of the biopharmaceutical company’s stock worth $250,000 after buying an additional 1,000 shares in the last quarter. Harvest Fund Management Co. Ltd bought a new stake in shares of CymaBay Therapeutics in the fourth quarter worth $26,000. Finally, China Universal Asset Management Co. Ltd. raised its holdings in CymaBay Therapeutics by 96.9% in the third quarter. China Universal Asset Management Co. Ltd. now owns 2,516 shares of the biopharmaceutical company’s stock valued at $38,000 after acquiring an additional 1,238 shares in the last quarter. 95.03% of the stock is currently owned by institutional investors and hedge funds.

CymaBay Therapeutics Company Profile

CymaBay Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing and providing therapies to treat liver and other chronic diseases. Its lead product candidate is seladelpar (MBX-8025), a selective agonist of peroxisome proliferator activated receptor delta for the treatments of primary biliary cholangitis (PBC).